Wanted pages
From Glioblastoma Treatments
Jump to navigationJump to search
List of non-existing pages with the most links to them, excluding pages which only have redirects linking to them. For a list of non-existent pages that have redirects linking to them, see the list of broken redirects.
Showing below up to 50 results in range #1 to #50.
- Not specified (80 links)
- 3 (54 links)
- 2 (40 links)
- 4 (40 links)
- 1 (20 links)
- Property:Has Toxicity Level (13 links)
- Property:Has Usefulness Rating (13 links)
- Property:Has treatment name (12 links)
- Not rated (9 links)
- 2.5 (6 links)
- Property:Has OS with (5 links)
- Property:Has OS without (5 links)
- Property:Has PFS with (5 links)
- Property:Has PFS without (5 links)
- " in your query was not closed by a matching " (4 links)
- CBD (Cannabidiol) (4 links)
- Cannabigerol (CBG) (4 links)
- Cannabis and Cannabis-derived Products (e.g., Sativex) (4 links)
- Ellagic Acid (4 links)
- Fish Oil (Omega-3 Fatty Acids: EPA and DHA) (4 links)
- Gamma-Linolenic Acid (GLA) (4 links)
- Garlic (Allium sativum) (4 links)
- Not applicable (4 links)
- PSK (Polysaccharide Krestin) and other polysaccharides (4 links)
- Perillyl Alcohol/Limonene (4 links)
- Sodium R Lipoate and Hydroxycitrate (METABLOC) (4 links)
- 23 months median survival, with 47% at 2 years (3 links)
- 5 (3 links)
- 6.1 months for all patients, 5.9 months for EGFR amplified patients (3 links)
- AVAglio trial: 16.8 months; RTOG trial: 15.7 months (3 links)
- Comparable to standard TMZ treatments, but timing affects management of side effects. (3 links)
- Data not specified (3 links)
- Gliadel: 13.9 months median survival; Combination with TMZ: Median survival ranges from 17 to 20.7 months (3 links)
- ICT-107 has demonstrated potential in extending progression-free and overall survival in GBM patients, especially in specific subgroups. Its ability to target multiple tumor-associated antigens may offer a broader immunogenic response. (3 links)
- Keppra (Levetiracetam) (3 links)
- Not applicable; studies focusing on PFS-6 as a primary endpoint (3 links)
- Not reached at a median follow-up of 5.8 months (3 links)
- Not specified in the provided text (3 links)
- PFS-6 value was 53% in a restricted patient population with overexpression of PDGFR (3 links)
- Phase II (3 links)
- Proton Beam Therapy (PBT) (3 links)
- Sativex (Nabiximols) (3 links)
- This vaccine represents a promising strategy by targeting CMV antigens present in GBM cells, potentially extending survival significantly beyond standard treatments. Initial results suggest substantial benefits for certain patient groups. (3 links)
- VT-122 (Propranolol and Etodolac combination) (3 links)
- 14-16 months with standard treatment. (2 links)
- 16 months (control group in EF-14 Trial) (2 links)
- 17% in the study of patients with tumors recurring after radiation; 38% in a study using PCV for tumors recurrent after radiation (and for some after prior chemotherapy); 13% in a study with PCV after Temodar failure (2 links)
- 1 out of 16 patients was alive after one year. (2 links)
- 20.9 months (Optune plus temozolomide, final EF-14 analysis) (2 links)
- 3.5 (2 links)
